Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Nivolumab in combination with ipilimumab and chemotherapy for untreated metastatic or recurrent non-small-cell lung cancer in patients whose tumours express PD-L1 with a tumour proportion score <1% with no EGFR or ALK genomic tumour mutations

Condition

Cancer

Respiratory

1 June 2026

-

Published on 06 Feb 2026
Last Updated on 01 Jun 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended nivolumab in combination with ipilimumab and chemotherapy for inclusion on the Medication Assistance Fund (MAF) for untreated metastatic or recurrent non-small-cell lung cancer (NSCLC) in patients whose tumours express programmed death-ligand 1 with a tumour proportion score <1% (PD-L1 <1%), with no EGFR or ALK genomic tumour mutations. The decision was based on unfavourable cost effectiveness compared with subsidised alternatives.

Nivolumab in combination with ipilimumab and chemotherapy will remain eligible for claims and benefits under MediShield Life (no subsidy) for untreated metastatic or recurrent NSCLC in patients with no EGFR or ALK genomic tumour mutations.

Clinical indication, subsidy class and MediShield Life claims eligibility for nivolumab and ipilimumab are provided in the Annex.

Guidance_Nivolumab in combination with ipilimumab and chemotherapy for untreated metastatic or recurrent non-small-cell lung cancer in patients whose tumours express PD-L1 with a tumour proportion score <1% with no EGFR or ALK genomic tumour mutations (1 Jun 2026) (opens in new tab)